Injectable CAB-PrEP
Preparing for roll‑out through joint national leadership
Injectable Cabotegravir (CAB‑PrEP), expected to be fully available from February 2026, represents a major step forward in HIV prevention for people who cannot use oral PrEP. As a long‑acting, two‑monthly injectable, it reduces adherence challenges and broadens prevention options across local systems.
This briefing document, developed in partnership with the English HIV & Sexual Health Commissioners’ Group (EHSHCG), brings together public health, commissioning and clinical perspectives to support local systems in preparing for roll‑out.
CAB‑PrEP arrives at a time of rising demand, increasing costs and significant workforce pressures in sexual health services. While it supports progress towards the HIV Action Plan, its introduction brings new operational, tariff and resource considerations that require coordinated planning across local authorities and providers.
We are recommending that local authorities:
- Use the NICE resource impact template to understand potential demand.
- Develop localised costing models tailored to local capacity and need.
- Work collaboratively with providers, commissioners and clinicians to assess workforce implications and ensure sustainable delivery.